Literature DB >> 21180880

Three-year follow-up study of respiratory and systemic manifestations of chronic obstructive pulmonary disease.

R Ferrari1, S E Tanni, M M Faganello, L M O Caram, P A Lucheta, I Godoy.   

Abstract

Few studies show patient outcomes over time in chronic obstructive pulmonary disease (COPD). In the present study, we monitored forced expiratory volume in the first second (FEV₁) and other manifestations of the disease over 3 years in 133 COPD patients (69% males, age = 65 ± 9 years, FEV₁ = 59 ± 25%) evaluated at baseline. During follow-up, 15 patients (11%) died and 23 (17%) dropped out. Measurements for 95 (72%) COPD patients alive after 3 years were analyzed. FEV₁, body mass index (BMI), 6-min walking distance (6MWD), Medical Research Council scale (MRC), Saint George's Respiratory Questionnaire (SGRQ), Charlson Comorbidity index, and BODE index were obtained at baseline and after 3 years. At baseline, 17 patients (18%) presented mild, 39% moderate, 19% severe, and 24% very severe COPD. Predicted FEV₁ % and BMI did not change over the period (P > 0.05). FEV₁ in liters [1.25 (0.96-1.72) vs 1.26 (0.88-1.60) L; P < 0.001], 6MWD (438 ± 86 vs 412 ± 100 m; P < 0.001), MRC [1 (1-2) vs 2 (1-3); P = 0.002], Charlson index [3 (3-4) vs 4 (3-5); P = 0.009], BODE index (2.2 ± 1.8 vs 2.6 ± 2.3; P = 0.008), and total SGRQ (42 ± 19 vs 44 ± 19%; P = 0.041) worsened after 3 years compared to baseline measurements. These data show that COPD patients deteriorated during the 3-year follow-up despite the fact that they had only minor modifications in airway obstruction and body composition. They support the need for comprehensive patient assessment to better identify disease progression.

Entities:  

Mesh:

Year:  2010        PMID: 21180880     DOI: 10.1590/s0100-879x2010007500150

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  8 in total

1.  Predictors of health status do not change over three-year periods and exacerbation makes difference in chronic obstructive pulmonary disease.

Authors:  Renata Ferrari; Suzana E Tanni; Laura M O Caram; Cristiane R Naves; Irma Godoy
Journal:  Health Qual Life Outcomes       Date:  2011-12-09       Impact factor: 3.186

Review 2.  Relationship between Dysphagia and Exacerbations in Chronic Obstructive Pulmonary Disease: A Literature Review.

Authors:  Eduardo Steidl; Carla Simone Ribeiro; Bruna Franciele Gonçalves; Natália Fernandes; Vívian Antunes; Renata Mancopes
Journal:  Int Arch Otorhinolaryngol       Date:  2014-11-06

3.  Functional outcomes in patients with chronic obstructive pulmonary disease: a multivariate analysis.

Authors:  Filipe T S Athayde; Danielle S R Vieira; Raquel R Britto; Verônica F Parreira
Journal:  Braz J Phys Ther       Date:  2014 Jan-Feb       Impact factor: 3.377

4.  Predictors of mortality in patients with COPD after 9 years.

Authors:  Robson Prudente; Estefânia Aparecida Thomé Franco; Carolina Bonfanti Mesquita; Renata Ferrari; Irma de Godoy; Suzana Erico Tanni
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-10-17

5.  Nine-Year Follow-Up of Interleukin 6 in Chronic Obstructive Pulmonary Disease - Complementary Results from Previous Studies.

Authors:  Robson Prudente; Renata Ferrari; Carolina Mesquita; Luiz Machado; Estefânia Franco; Irma Godoy; Suzana Tanni
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-11-03

Review 6.  Pathophysiology of cachexia and characteristics of dysphagia in chronic diseases.

Authors:  Haruyo Matsuo; Kunihiro Sakuma
Journal:  Asia Pac J Oncol Nurs       Date:  2022-07-22

7.  Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease.

Authors:  Renata Ferrari; Suzana E Tanni; Laura M O Caram; Corina Corrêa; Camila R Corrêa; Irma Godoy
Journal:  Respir Res       Date:  2013-02-20

Review 8.  Brazilian studies on pulmonary function in COPD patients: what are the gaps?

Authors:  Agnaldo José Lopes; Pedro Lopes de Melo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-07-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.